Cargando…
Correlates of neutralizing/SARS-CoV-2-S1-binding antibody response with adverse effects and immune kinetics in BNT162b2-vaccinated individuals
While mRNA vaccines against SARS-CoV-2 are exceedingly effective in preventing symptomatic infection, their immune response features remain to be clarified. In the present prospective study, 225 healthy individuals in Japan, who received two BNT162b2 doses, were enrolled. Correlates of BNT162b2-elic...
Autores principales: | Maeda, Kenji, Amano, Masayuki, Uemura, Yukari, Tsuchiya, Kiyoto, Matsushima, Tomoko, Noda, Kenta, Shimizu, Yosuke, Fujiwara, Asuka, Takamatsu, Yuki, Ichikawa, Yasuko, Nishimura, Hidehiro, Kinoshita, Mari, Matsumoto, Shota, Gatanaga, Hiroyuki, Yoshimura, Kazuhisa, Oka, Shin-ichi, Mikami, Ayako, Sugiura, Wataru, Sato, Toshiyuki, Yoshida, Tomokazu, Shimada, Shinya, Mitsuya, Hiroaki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8613264/ https://www.ncbi.nlm.nih.gov/pubmed/34819514 http://dx.doi.org/10.1038/s41598-021-01930-y |
Ejemplares similares
-
Correlates of Neutralizing/SARS-CoV-2-S1-binding Antibody Response with Adverse Effects and Immune Kinetics in BNT162b2-Vaccinated Individuals
por: Maeda, Kenji, et al.
Publicado: (2021) -
Neutralization against Omicron sublineages (BA.2/BA.5/BQ.1.1/XBB/XBB.1.5) in bivalent BNT162b2-vaccinated HCWs with or without risk factors, or following BT infection with Omicron
por: Amano, Masayuki, et al.
Publicado: (2023) -
Third-Dose BNT162b2 Vaccination Elicits Markedly High-Level SARS-CoV-2–Neutralizing Antibodies in Vaccinees Who Responded Poorly to a Second Dose in Japan
por: Amano, Masayuki, et al.
Publicado: (2022) -
Combination of a Latency-Reversing Agent With a Smac Mimetic Minimizes Secondary HIV-1 Infection in vitro
por: Hattori, Shin-ichiro, et al.
Publicado: (2018) -
Restoration of Neutralization Activity Against Omicron BA.2 and BA.5 in Older Adults and Individuals With Risk Factors Following the Fourth Dose of Severe Acute Respiratory Syndrome Coronavirus 2 BNT162b2 Vaccine
por: Amano, Masayuki, et al.
Publicado: (2022)